NCT03678883Phase 2Active not recruiting

9-ING-41 in Patients With Advanced Cancers

Study sponsor: Actuate Therapeutics Inc. · ACTU

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-06Estimated

Enrollment · participants350Estimated

Source updated2026-04-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-03 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2025-01

+ Updated value

2026-06

Check registry source

Study details

Conditions studied

Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory Non-Hodgkin Lymphoma; Pancreatic Adenocarcinoma; Resistant Cancer; Neoplasm Metastasis; Neoplasm of Bone; Neoplasm, Breast; Neoplasm of Lung; Neoplasms,Colorectal; Neoplasms Pancreatic; Malignant Glioma; Malignancies; Malignancies Multiple; Bone Metastases; Bone Neoplasm; Bone Cancer; Pancreas Cancer; Pancreatic Neoplasms; Breast Neoplasms; Acute T Cell Leukemia Lymphoma

Treatments or interventions studied

9-ING-41Drug
Gemcitabine - 21 day cycleDrugAlso known as Gemzar
Doxorubicin.DrugAlso known as Doxil, Adriamycin
LomustineDrugAlso known as CCNU, Gleostine
Carboplatin.DrugAlso known as Paraplatin
Nab paclitaxel.DrugAlso known as Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel
Paclitaxel.DrugAlso known as Taxol
Gemcitabine - 28 day cycleDrugAlso known as Gemzar
IrinotecanDrugAlso known as Camptosar

Primary outcomes · main study measures

Read the study measures

measure: Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03; description: The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.; timeFrame: 3 months to 3 years; measure: Part 3 Arm B; description: To determine the 1-year survival rate of patients treated on the 9-ING-41 schedule chosen from the run-in stage of the study compared to the control arm; timeFrame: 3 months to 3 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history